<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580343</url>
  </required_header>
  <id_info>
    <org_study_id>tofacitinib_eye_disease</org_study_id>
    <nct_id>NCT03580343</nct_id>
  </id_info>
  <brief_title>Tofacitinib for Inflammatory Eye Disease</brief_title>
  <official_title>Tofacitinib for the Treatment of Inflammatory Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-infectious inflammatory eye disease, such as uveitis and scleritis, is a chronic,&#xD;
      auto-immune process that leads to vision loss. While steroids are effective in the short&#xD;
      term, the side-effect profile of chronic steroid use necessitates the identification of&#xD;
      effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the&#xD;
      signaling pathways of multiple inflammatory cytokines. The investigators plan to evaluate&#xD;
      whether tofacitinib may have efficacy for patients with uveitis and / or scleritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single-site, open-label investigation of tofacitinib for&#xD;
      refractory uveitis. The study will be for 24 weeks, with potential 1-year extension for&#xD;
      treatment responders. The patients will self-administer the medication.&#xD;
&#xD;
      Eligible patients would be those patients with a diagnosis of uveitis who meet the following&#xD;
      criteria:&#xD;
&#xD;
        1. Disease sufficiently severe to require treatment with systemic corticosteroids, and&#xD;
&#xD;
        2. Referred from Ophthalmology to Rheumatology or Uveitis specialist for a steroid-sparing&#xD;
           agent&#xD;
&#xD;
      For patients naive to oral steroid-sparing therapy (e.g., methotrexate, azathioprine, or&#xD;
      mycophenolate), tofacitinib will be initiated as monotherapy. For patients who have failed or&#xD;
      had only a partial response to oral steroid-sparing therapy, tofacitinib will be initiated as&#xD;
      an add-on therapy. For patients intolerant to a conventional agent, tofacitinib will be&#xD;
      initiated as replacement monotherapy. For patients who have failed biologic therapy (e.g.&#xD;
      adalimumab), biologic therapy will be discontinued and tofacitinib will be initiated as&#xD;
      replacement therapy without change to concurrent conventional steroid-sparing agents. Study&#xD;
      visits will occur at baseline/enrollment, and weeks 4, 8, 12, 16, &amp; 24 (+/- 2 weeks). Clinic&#xD;
      visits may occur more frequently as determined by the treating physician. Laboratory&#xD;
      monitoring (Table 1) will be obtained according to standard of care for drug toxicity&#xD;
      monitoring. Clinical responses will be evaluated at 24 weeks, with the primary outcome&#xD;
      defined as treatment failure.&#xD;
&#xD;
      All patients will undergo a predetermined oral steroid taper starting at 60mg of prednisone&#xD;
      (or equivalent) and tapering over 14 weeks (Table 2). All patients will undergo a&#xD;
      predetermined topical steroid drop taper starting at their current dose (Table 3).&#xD;
&#xD;
      Patients will have an ophthalmological evaluation by their treating ophthalmologist at&#xD;
      Washington University. Steroid sparing therapy will be managed by rheumatologists or uveitis&#xD;
      specialists at Washington University. All patients will be evaluated for an associated&#xD;
      systemic rheumatologic condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">April 4, 2021</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Failure (Composite Outcome)</measure>
    <time_frame>180 days</time_frame>
    <description>new inflammatory lesions relative to baseline OR 2-step increase in anterior chamber cell or vitreous haze OR worsening of visual acuity by two or more rows on ETDRS chart</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Uveitis</condition>
  <condition>Scleritis</condition>
  <arm_group>
    <arm_group_label>Tofacitinib Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>11mg extended-release tofacitinib, once daily, oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib</intervention_name>
    <description>tofacitinib extended release, 11mg, daily, oral</description>
    <arm_group_label>Tofacitinib Treatment</arm_group_label>
    <other_name>TOFA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of uveitis&#xD;
&#xD;
          -  a clinical response to steroids&#xD;
&#xD;
          -  active disease requiring at least 10mg of prednisone daily (or steroid equivalent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  suspected or confirmed ocular infection&#xD;
&#xD;
          -  chronic or recurring infections, such as HIV&#xD;
&#xD;
          -  renal insufficiency that would preclude safe administration of tofacitinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn M Hassman, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University in Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <results_first_submitted>December 2, 2020</results_first_submitted>
  <results_first_submitted_qc>January 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2021</results_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Scleritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03580343/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Active uveitis despite at least 10mg prednisone for 2 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tofacitinib Treatment</title>
          <description>tofacitinib: tofacitinib extended release, 11mg, daily, oral</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tofacitinib</title>
          <description>single arm- tofacitinib 11mg daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" lower_limit="49" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Failure (Composite Outcome)</title>
        <description>new inflammatory lesions relative to baseline OR 2-step increase in anterior chamber cell or vitreous haze OR worsening of visual acuity by two or more rows on ETDRS chart</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib Treatment</title>
            <description>tofacitinib: tofacitinib extended release, 11mg, daily, oral</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure (Composite Outcome)</title>
          <description>new inflammatory lesions relative to baseline OR 2-step increase in anterior chamber cell or vitreous haze OR worsening of visual acuity by two or more rows on ETDRS chart</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tofacitinib Treatment</title>
          <description>tofacitinib: tofacitinib extended release, 11mg, daily, oral</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cutaneous melanoma</sub_title>
                <description>right upper extremity melanoma, with negative sentinel lymph nodes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>squamous cell carcinoma</sub_title>
                <description>squamous cell carcinoma on arm, fast-growing, history of multiple squamous cell carcinomas removed</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lynn Hassman, Assistant Professor and Study PI</name_or_title>
      <organization>Washington University in St. Louis</organization>
      <phone>3142730341</phone>
      <email>lhassman@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

